ABSTRACT
Although the efficacy of maintenance pharmacotherapy for the prevention of recurrence in major depressive disorder (MDD) is well documented, few studies have tested the efficacy of psychotherapy as a maintenance treatment. The authors examined the efficacy of the cognitive-behavioral analysis system of psychotherapy (CBASP) as a maintenance treatment for chronic forms of MDD. Eighty-two patients who had responded to acute and continuation phase CBASP were randomized to monthly CBASP or assessment only for 1 year. Significantly fewer patients in the CBASP than assessment only condition experienced a recurrence. The 2 conditions also differed significantly on change in depressive symptoms over time. These findings support the use of CBASP as a maintenance treatment for chronic forms of MDD.
Subject(s)
Cognitive Behavioral Therapy/methods , Depressive Disorder, Major/therapy , Adolescent , Adult , Aged , Chronic Disease , Depressive Disorder, Major/diagnosis , Diagnostic and Statistical Manual of Mental Disorders , Female , Humans , Male , Middle AgedABSTRACT
Although many studies report that the therapeutic alliance predicts psychotherapy outcome, few exclude the possibility that this association is accounted for by 3rd variables, such as prior improvement and prognostically relevant patient characteristics. The authors treated 367 chronically depressed patients with the cognitive-behavioral analysis system of psychotherapy (CBASP), alone or with medication. Using mixed effects growth-curve analyses, they found the early alliance significantly predicted subsequent improvement in depressive symptoms after controlling for prior improvement and 8 prognostically relevant patient characteristics. In contrast, neither early level nor change in symptoms predicted the subsequent level or course of the alliance. Patients receiving combination treatment reported stronger alliances with their psychotherapists than patients receiving CBASP alone. However, the impact of the alliance on outcome was similar for both treatment conditions.
Subject(s)
Antidepressive Agents, Second-Generation/therapeutic use , Cognitive Behavioral Therapy , Depressive Disorder, Major/therapy , Dysthymic Disorder/therapy , Professional-Patient Relations , Triazoles/therapeutic use , Adult , Combined Modality Therapy , Comorbidity , Depressive Disorder, Major/psychology , Dysthymic Disorder/psychology , Female , Humans , Male , Middle Aged , Outcome and Process Assessment, Health Care , Piperazines , RecurrenceABSTRACT
Chronic forms of depression are more common and impairing than is generally recognized. This article introduces an In Session issue devoted to dysthymic disorder and chronic depression, and it reviews current knowledge about these disorders. First, we discuss nosological issues, followed by a summary of potential risk factors. Finally, the naturalistic course of chronic depression is described and implications for clinical practice are discussed.
